# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA857209 | F | Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (F)) virus-induced cytopathicity by 50% | Human alphaherpesvirus 1 | 9 | organism-based format | Scientific Literature | ||
2. | ALA691850 | F | Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (KOS)) virus-induced cytopathicity by 50% | Human alphaherpesvirus 1 | 13 | organism-based format | Scientific Literature | ||
3. | ALA691851 | F | Minimum inhibitory concentration required to reduce herpes simplex virus-1 (HSV-1 (McIntyre)) virus-induced cytopathicity by 50% | Human alphaherpesvirus 1 | 9 | organism-based format | Scientific Literature | ||
4. | ALA880020 | F | Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (196)) virus-induced cytopathicity by 50% | Human alphaherpesvirus 2 | 9 | organism-based format | Scientific Literature | ||
5. | ALA692370 | F | Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (G)) virus-induced cytopathicity by 50% | Human alphaherpesvirus 2 | 13 | organism-based format | Scientific Literature | ||
6. | ALA692371 | F | Minimum inhibitory concentration required to reduce herpes simplex virus-2 (HSV-2 (Lyons)) virus-induced cytopathicity by 50% | Human alphaherpesvirus 2 | 9 | organism-based format | Scientific Literature | ||
7. | ALA810190 | F | Minimum inhibitory concentration required to reduce thymidine kinase deficient-HSV-1 (B2006) virus-induced cytopathicity by 50% | Human alphaherpesvirus 1 | 8 | organism-based format | Scientific Literature | ||
8. | ALA810191 | F | Minimum inhibitory concentration required to reduce thymidine kinase deficient-HSV-1 (VMW 1837) virus-induced cytopathicity by 50% | Human alphaherpesvirus 1 | 9 | organism-based format | Scientific Literature | ||
9. | ALA810193 | F | Minimum inhibitory concentration required to reduce TK-VZV (YS/R) virus-induced cytopathicity by 50% | Human alphaherpesvirus 3 | 13 | organism-based format | Scientific Literature | ||
10. | ALA816092 | B | Binding affinity towards HSV-1 thymidine kinase | 18 | single protein format | Scientific Literature | |||
11. | ALA816364 | F | Minimum inhibitory concentration required to reduce VSV virus-induced cytopathicity by 50% | Vesicular stomatitis virus | 13 | organism-based format | Scientific Literature | ||
12. | ALA816365 | F | Minimum inhibitory concentration required to reduce vesicular somatitis virus (VSV (YS)) virus-induced cytopathicity by 50% | Vesicular stomatitis virus | 12 | organism-based format | Scientific Literature | ||
13. | ALA816374 | F | Minimum inhibitory concentration required to reduce vaccinia virus (VV) virus-induced cytopathicity by 50% | Vaccinia virus | 13 | organism-based format | Scientific Literature | ||
14. | ALA824528 | F | Minimum inhibitory concentration required to reduce Varicella-Zoster virus (VZV (Oka)) virus-induced cytopathicity by 50% | Human alphaherpesvirus 3 | 13 | organism-based format | Scientific Literature | ||
15. | ALA824223 | F | Minimum concentration required to cause a microscopically detectable alteration of human cells morphology | Homo sapiens | 3 | cell-based format | Scientific Literature | ||
16. | ALA824224 | F | Minimum inhibitory concentration required to reduce virus-induced cell growth by 50% | Homo sapiens | 2 | cell-based format | Scientific Literature |